Portfolio

We seek investments in innovative companies that are developing first-in-class products for growth markets. Investments have been made in various therapeutic areas, including oncology, inflammation, cardiovascular, metabolic and CNS.

Fibrex Medical - Austria

Fund engagement:2006Activity:Drug development
Reperfusion injury
Status:Exited - LicensingContact:www.fibrexmedical.com
 

Elara Phamraceuticals - Germany

Fund engagement:2006Activity:Drug development
HIF pathway
Status:Pre-clinical developmentContact:www.elarapharma.com
 

Lipid Therapeutics - Germany

Fund engagement:2008Activity:Drug development
Colitis ulcerosa
Status:Partnered - Phase IIBContact:www.lipid-therapeutics.com
 

Affectis Pharmaceuticals - Germany

Fund engagement:2005Activity:Drug development
Depression
Status:Clinical phase IIAContact:www.affectis.com
 

Immatics - Germany

Fund engagement:2004Activity:Drug development
Cancer vaccines
Status:Clinical phase IIAContact:www.immatics.com
 

Endoart - Switzerland

Fund engagement:2006Activity:Medtech
Obesity
Status:Exited - AquisitionContact:n.a.
 

Vasopharm - Germany

Fund engagement:2006Activity:Drug development
Traumatic brain injury
Status:Clinical phase IIAContact:www.vasopharm.com
 

Hybricore - Germany

Fund engagement:2003Activity:Services
Antibody production
Status:Exited - LicensingContact:n.a.
 

Combinature - Germany

Fund engagement:2006Activity:Drug development
Anti-infectives
Status:Exited - Secondary transactionContact:n.a.
 

Jado Technologies - Germany

Fund engagement:2006Activity:Drug development
Allergy
Status:Clinical phase IIAContact:www.jado-tech.com
 

Cenix Bioscience - Germany

Fund engagement:2002Activity:Services
RNAi based target discovery
Status:ProfitableContact:www.cenix-bioscience.com
 

ArthroKinetics - Germany

Fund engagement:2003Activity:Medtech
Cartilage replacement
Status:Exited - IPOContact:www.arthro-kinetics.com
 
"The EMBL Ventures team stands out through its professional competence, loyalty, consistency and intense interest in the development of Fibrex. As a consequence, convincing solutions are found in a timely fashion, even in difficult situations. EMBL Ventures offers access to its broad scientific and industry network, which is a tremendous support to achieve our company goals."
Dr. Rainer Henning; CEO, Fibrex Medical, Vienna